HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Abstract
Nasopharyngeal specimens for culture of Chlamydia pneumoniae were obtained from patients participating in two pneumonia treatment studies: an open study of 400 mg moxifloxacin orally, qds for 10 days and a randomized, double-blind comparison of moxifloxacin, 400 mg orally, qds versus clarithromycin, 500 mg orally, bd, both for 10 days. C. pneumoniae was eradicated from the nasopharynx of seven of ten (70%) microbiologically evaluable patients who were treated with moxifloxacin and four of four who were treated with clarithromycin. Minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of 21 isolates of C. pneumoniae from 18 patients obtained before and after therapy were performed against moxifloxacin and clarithromycin. The MIC(90)s and MBC(90)s for moxifloxacin and clarithromycin were 1 and 0.06 mg/l, respectively. The MICs and MBCs against moxifloxacin of six isolates from three persistently infected patients who were treated with the drug were the same at baseline and follow-up. The persistence of C. pneumoniae after treatment with moxifloxacin was probably not due to the emergence of resistance.
AuthorsM R Hammerschlag, P M Roblin
JournalInternational journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 15 Issue 2 Pg. 149-52 (Jul 2000) ISSN: 0924-8579 [Print] NETHERLANDS
PMID10854812 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Clarithromycin
  • moxifloxacin
Topics
  • Administration, Oral
  • Adolescent
  • Adult
  • Anti-Bacterial Agents (pharmacology, therapeutic use)
  • Anti-Infective Agents (pharmacology, therapeutic use)
  • Aza Compounds
  • Chlamydia Infections (drug therapy, microbiology)
  • Chlamydophila pneumoniae (drug effects, isolation & purification)
  • Clarithromycin (pharmacology, therapeutic use)
  • Community-Acquired Infections (drug therapy, microbiology)
  • Fluoroquinolones
  • Humans
  • Inhibitory Concentration 50
  • Microbial Sensitivity Tests
  • Nasopharynx (microbiology)
  • Pneumonia, Bacterial (drug therapy, microbiology)
  • Quinolines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD